Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
| Status: | Archived |
|---|---|
| Conditions: | Anxiety, Depression, Major Depression Disorder (MDD), Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2008 |
| End Date: | March 2012 |
Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
The primary objective is to test the hypothesis that quetiapine XR (Extended Release)
monotherapy or adjunctive therapy to antidepressant is superior to placebo monotherapy or
placebo adjunctive therapy to antidepressant(s) in the acute treatment of depression
symptoms in patients with MDD and comorbid GAD. The secondary objectives are to test the
hypotheses that quetiapine XR is superior to placebo in the reduction of anxiety symptoms in
patients with major depressive disorder and comorbid generalized anxiety disorder, the
improvement of the quality of sleep in patients with major depressive disorder and comorbid
generalized anxiety disorder and the improvement of the quality of life in patients with
major depressive disorder and comorbid generalized anxiety disorder.
We found this trial at
1
site
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
